MedTrace Logo

Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors

NCT07041112 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-06-27

No results posted yet for this study

Summary

This retrospective observational study aims to evaluate the long-term survival of biologic therapies in adult patients with moderate-to-severe cutaneous psoriasis, with or without psoriatic arthritis, over a period of up to 10 years. The study investigates the influence of clinical, metabolic, and genetic factors, including SNPs and metabolic syndrome components, on treatment durability. Data were obtained from a single-centre cohort treated in routine clinical practice. This analysis seeks to identify predictors of therapeutic response and to explore pharmacogenetic profiles that may inform personalized treatment strategies.

Conditions

  • Psoriasis
  • Psoriatic Arthritis (PsA)
  • Cardiovascular Risk Factors
  • Metabolic Syndrome (MetS)
  • Drug Survival
  • Pharmacogenetics

Interventions

DRUG

Biologic therapy for psoriasis

Exposure to systemic biologic drugs for psoriasis, including TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab), IL-12/23 inhibitors (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab, brodalumab), and IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab). Treatments were prescribed as part of routine clinical care.

Sponsors & Collaborators

  • Hospital Universitario Reina Sofia de Cordoba

    collaborator OTHER_GOV

  • Universidad de Córdoba

    collaborator OTHER

  • Maimonides Institute for Biomedical Research of Cordoba (IMIBIC)

    collaborator UNKNOWN

  • Juan Ruano Ruiz

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-01
Primary Completion
2023-03-01
Completion
2024-06-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07041112 on ClinicalTrials.gov